Chinook Therapeutics, Inc.

NasdaqGS:KDNY Stock Report

Market Cap: US$2.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chinook Therapeutics Management

Management criteria checks 3/4

Chinook Therapeutics' CEO is Eric Dobmeier, appointed in Apr 2019, has a tenure of 4.33 years. total yearly compensation is $4.84M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $12.16M. The average tenure of the management team and the board of directors is 2.2 years and 3.5 years respectively.

Key information

Eric Dobmeier

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage12.42%
CEO tenure4.3yrs
CEO ownership0.4%
Management average tenure2.2yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Analysis Article • May 28

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 14

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Aug 31

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, Vera Therapeutics and other peers. BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2023. KDNY is a Buy and I suggest accumulating dips to high-teens. Key risks include emerging competition in IgAN as well as disappointing pivotal readout for atrasentan.
Analysis Article • Aug 12

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

One thing we could say about the analysts on Chinook Therapeutics, Inc. ( NASDAQ:KDNY ) - they aren't optimistic...
Seeking Alpha • Aug 08

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chinook Therapeutics press release (NASDAQ:KDNY): Q2 GAAP EPS of -$0.61 in-line. Revenue of $0.42M (+1300.0% Y/Y) in-line.
Seeking Alpha • Jul 05

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Chinook Therapeutics (NASDAQ:KDNY) on Tuesday said it had got European orphan drug designation for its BION-1301 treatment for primary IgA nephropathy, a type of kidney disease. The European drug regulator's orphan designation is given to medicines developed for rare, life-threatening diseases. The orphan drug designation for BION-1301 follows a positive opinion from a European drug regulator committee. KDNY will be evaluating BION-1301 in a phase 3 study in 2023. KDNY stock closed largely unchanged at $17.51 on Friday.

CEO Compensation Analysis

How has Eric Dobmeier's remuneration changed compared to Chinook Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$246m

Mar 31 2023n/an/a

-US$216m

Dec 31 2022US$5mUS$601k

-US$188m

Sep 30 2022n/an/a

-US$118m

Jun 30 2022n/an/a

-US$92m

Mar 31 2022n/an/a

-US$97m

Dec 31 2021US$4mUS$547k

-US$103m

Sep 30 2021n/an/a

-US$160m

Jun 30 2021n/an/a

-US$149m

Mar 31 2021n/an/a

-US$114m

Dec 31 2020US$6mUS$438k

-US$82m

Compensation vs Market: Eric's total compensation ($USD4.84M) is about average for companies of similar size in the US market ($USD6.59M).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.

CEO

Eric Dobmeier (54 yo)

4.3yrs
Tenure
US$4,841,699
Compensation

Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Eric Dobmeier
President4.3yrsUS$4.84m0.42%
$ 12.2m
Tom Frohlich
Chief Operating Officer2.2yrsUS$2.02m0.21%
$ 6.1m
Andrew King
Chief Scientific Officer2.2yrsUS$2.23m0.027%
$ 773.8k
Eric Bjerkholt
Chief Financial Officer2.8yrsno data0.054%
$ 1.6m
Sukhi Thethy
Senior Vice President of Finance & Accountingless than a yearno datano data
Noopur Liffick
Senior Vice President of Investor Relations & Corporate Communicationsno datano datano data
Kirk Schumacher
Senior VP & General Counselno datano datano data
Jodi Jamieson
Senior Vice President of Human Resourcesno datano datano data
Alan Glicklich
Executive Officer3.3yrsUS$2.41m0.011%
$ 318.7k
Delphine Imbert
Senior Vice President of CMC & Technical Operations2.3yrsno datano data
Charlotte Jones-Burton
Senior Vice President of Product Development & Strategy1.6yrsno datano data
Andrew Oxtoby
Chief Commercial Officerless than a yearno datano data
2.2yrs
Average Tenure
49yo
Average Age

Experienced Management: KDNY's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Eric Dobmeier
President4.3yrsUS$4.84m0.42%
$ 12.2m
Michelle Griffin
Independent Director2.8yrsUS$233.60k0.0046%
$ 133.4k
Srinivas Akkaraju
Independent Director4.1yrsUS$227.60k0.0046%
$ 133.4k
William Greenman
Independent Director13.2yrsUS$233.10k0.033%
$ 955.0k
Mahesh Krishnan
Independent Director1.4yrsUS$451.98k0.0018%
$ 51.6k
Jerel Davis
Independent Lead Director4.7yrsUS$244.60k0.62%
$ 18.1m
Robert Azelby
Independent Directorless than a yearno data0%
$ 0
Dolca Thomas
Independent Director2.8yrsUS$217.60k0.019%
$ 537.1k
3.5yrs
Average Tenure
54.5yo
Average Age

Experienced Board: KDNY's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/12 11:13
End of Day Share Price 2023/08/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chinook Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antonia BorovinaBloom Burton & Co.
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI